Search company, investor...

Founded Year



Series A | Alive

Total Raised


Last Raised

$5M | 23 yrs ago

About Alerion Biomedical

Alerion Biomedical Inc. in San Diego is developing products for the detection, characterization and treatment of disease. The company is developing technologies aimed at studying and managing major diseases including cancer, vascular disorders and hepatobiliary disease. Alerion's latest product line, Fenestra, is revolutionizing the way in vivo imaging is used in basic research and drug development. Founded initially in 1997 as MetaProbe LLC by Research Corporation Technologies and the California Institute of Technology, Alerion Biomedical has grown to encompass a broad range of drug-delivery and medical imaging technologies. Advanced Research Technologies Inc., a Canadian medical device company, acquired substantially all of the imaging technology and product assets of Alerion in March 2006. ART is actively promoting the Fenestra product line.

Headquarters Location

6370 Nancy Ridge Dr #106

San Diego, California, 92121,

United States



Alerion Biomedical Frequently Asked Questions (FAQ)

  • When was Alerion Biomedical founded?

    Alerion Biomedical was founded in 1997.

  • Where is Alerion Biomedical's headquarters?

    Alerion Biomedical's headquarters is located at 6370 Nancy Ridge Dr, San Diego.

  • What is Alerion Biomedical's latest funding round?

    Alerion Biomedical's latest funding round is Series A.

  • How much did Alerion Biomedical raise?

    Alerion Biomedical raised a total of $5M.

  • Who are the investors of Alerion Biomedical?

    Investors of Alerion Biomedical include California Institute of Technology and Advanced Research Technologies.

  • Who are Alerion Biomedical's competitors?

    Competitors of Alerion Biomedical include Life Line Screening, Flex Biomedical, Aviir, Nodality, diaDexus and 7 more.


Compare Alerion Biomedical to Competitors

Xeptagen S.p.A.

XEPTAGEN SpA is engaged in the discovery and validation of molecular markers in order to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the platform technology Combinatorial Proteomic, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. The company's mission includes creating tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.


StageMark is a healthcare company that intends to provide an early identification and monitoring solution for inflammatory diseases such as lupus.

Viridis Diagnostics

Viridis' equipment is a disease marker testing platform to be used at point-of-care.


Litholink offers metabolic evaluations for kidney stone formers.


JJET is committed to the development, production, and sales of products in the field of electrophysiology; the products mainly include a three-dimensional cardiac mapping system, multi-channel physiological recorder, cardiac electrophysiological stimulator, cardiac radiofrequency ablation device, cold saline perfusion pump, cardiac electrophysiological mapping catheter, cardiac radiofrequency ablation catheter, nerve radiofrequency treatment instrument. The company was founded in 1991 and is based in Chengdu, China.

MetaMol Theranostics

MetaMol aims to develop diagnostics for the ability of cancer to spread and to supplement existing cancer therapies with anti-metastasis drugs.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.